Prognostic Value of IL-10 and Its Relationship with Disease Stage in Iranian Patients with Multiple Myeloma.
Shekarriz R et al.Asian Pac J Cancer Prev. 2018 Jan 27;19(1):27-32.

Discriminating Depth of Response to Therapy in Multiple Myeloma Using Whole-body Diffusion-weighted MRI with Apparent Diffusion Coefficient: Preliminary Results From a Single-center Study.
Wu C et al. Acad Radiol. 2018 Jan 16. pii: S1076-6332(17)30518-4. doi: 10.1016/j.acra.2017.12.008. [Epub ahead of print].

Calorimetric markers for monitoring of multiple myeloma and Waldenström’s macroglobulinemia patients.
Todinova S et al. Eur Biophys J. 2018 Jan 23. doi: 10.1007/s00249-018-1277-3. [Epub ahead of print].

Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma.
Chen X et al. Oncotarget. 2017 Nov 9;8(68):112685-112696. doi: 10.18632/oncotarget.22340. eCollection 2017 Dec 22.

A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma.
Vallet S et al. Leuk Lymphoma. 2018 Jan 18:1-8. doi: 10.1080/10428194.2017.1421757. [Epub ahead of print].

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.
Merz M et al. Blood Adv. 2017 Dec 27;2(1):1-9. doi: 10.1182/bloodadvances.2017013334. eCollection 2018 Jan 9.

STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma.
Jung SH et al. Blood Res. 2017 Dec;52(4):293-299. doi: 10.5045/br.2017.52.4.293. Epub 2017 Dec 26.

PRDI-BF1 and PRDI-BF1P isoform expressions correlate with disease status in multiple myeloma patients.
Buda G et al. Hematol Rep. 2017 Dec 22;9(4):7201. doi: 10.4081/hr.2017.7201. eCollection 2017 Dec 22.

Heavy/light chain assay as a biomarker for diagnosis and follow-up of multiple myeloma.
Chae H et al. Clin Chim Acta. 2018 Jan 8;479:7-13. doi: 10.1016/j.cca.2018.01.010. [Epub ahead of print].

Whole-body ultra-low dose CT using spectral shaping for detection of osteolytic lesion in multiple myeloma.
Suntharalingam S et al. Eur Radiol. 2018 Jan 10. doi: 10.1007/s00330-017-5243-8. [Epub ahead of print].

Flow Cytometric Aberrancies in Plasma Cell Myeloma and MGUS – Correlation with Laboratory Parameters.
Gupta S et al. Cytometry B Clin Cytom. 2018 Jan 6. doi: 10.1002/cyto.b.21624. [Epub ahead of print].

Copper-64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma.
Caserta E et al. Blood. 2018 Jan 4. pii: blood-2017-09-807263. doi: 10.1182/blood-2017-09-807263. [Epub ahead of print].

Panoramic and skull imaging may aid in the identification of multiple myeloma lesions.
Faria KM et al. Med Oral Patol Oral Cir Bucal. 2018 Jan 1;23(1):e38-e43. doi: 10.4317/medoral.22123.

Interpretation criteria for FDG PET/CT in multiple myeloma(IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).
Nanni C et al. Eur J Nucl Med Mol Imaging. 2017 Dec 21. doi: 10.1007/s00259-017-3909-8. [Epub ahead of print].

N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma.
Chen J et al. BMC Cancer. 2017 Dec 21;17(1):881. doi: 10.1186/s12885-017-3891-3.

Molecular detection of minimal residual disease in multiple myeloma.
Bai Yet al. Br J Haematol. 2017 Dec 19. doi: 10.1111/bjh.15075. [Epub ahead of print].

CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens.
Qin XY et al. Ann Hematol. 2017 Dec 21. doi: 10.1007/s00277-017-3203-7. [Epub ahead of print].